Ghavami Mahdi, Shiraishi Takehiko, Nielsen Peter E
Department of Cellular and Molecular Medicine, University of Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.
ACS Appl Bio Mater. 2020 Feb 17;3(2):1018-1025. doi: 10.1021/acsabm.9b01022. Epub 2020 Jan 30.
Phospholipase sensitive liposomes (PSLs) have attracted great attention in targeted anticancer drug delivery due to cargo release triggered by tumor-secreted phospholipase A (sPLA). Such liposomes could also serve as a vehicle for tissue-specific delivery of antisense therapeutics to (solid) tumors. While extensive studies on developing PSL formulations for small molecules exist, hardly any data are available on delivering larger molecules such as antisense agents. The present study demonstrates PSL encapsulation and phospholipase A triggered the release of a splice correcting, antisense octaarginine-peptide nucleic acid (octaarginine-PNA) conjugate. The results show that, although PNA can be efficiently encapsulated in PSL and also released using sPLA in serum-free conditions, the release is inhibited in the presence of serum. This is ascribed to the adsorption of serum proteins, including serum albumin and apolipoprotein C-III, to the surface of PSL (corona formation) and consequent prevention of sPLA-mediated PNA release.
磷脂酶敏感脂质体(PSLs)由于肿瘤分泌的磷脂酶A(sPLA)触发的药物释放,在靶向抗癌药物递送方面引起了极大关注。这种脂质体还可作为将反义治疗剂组织特异性递送至(实体)肿瘤的载体。虽然已有大量关于开发小分子PSL制剂的研究,但关于递送反义剂等大分子的可用数据却很少。本研究证明了PSL对一种剪接校正反义八聚精氨酸 - 肽核酸(八聚精氨酸 - PNA)缀合物的包封以及磷脂酶A触发的释放。结果表明,虽然PNA可以有效地包封在PSL中,并且在无血清条件下也能通过sPLA释放,但在有血清存在时释放受到抑制。这归因于血清蛋白(包括血清白蛋白和载脂蛋白C-III)吸附到PSL表面(形成冠状物),从而阻止了sPLA介导的PNA释放。